Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00464256 · ClinicalTrials.gov registry record · Phase 3
Comparison of Efficacy and Safety of Rimonabant 20mg/Day Versus Placebo in Smoking Cessation
A Phase 3 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 3
- Development phase
- 533
- Enrollment target
NCT00464256: Completed Phase 3 study, sponsored by Sanofi.
NCT00464256 is a Phase 3 study that has completed, run by Sanofi. The registered enrollment target is 533 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (31% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00464256, a Phase 3 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 533 participants
- Enrollment target
Study Summary
The primary objective is to assess the efficacy a 20mg/day fixed dose of rimonabant versus placebo on abstinence from tobacco use in cigarette smoker. The secondary objective is to evaluate the effects of rimonabant on craving and weight and on the clinical and biological safety and tolerability of rimonabant in a population of cigarette tobacco smokers during a 10-week treatment period.
Interventions
- DRUG rimonabant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 533 participants |
| Start Date | 2004-04 |
| Est. Completion | 2004-11 |
| Phase | Phase 3 |
What the finished NCT00464256 record still lists
NCT00464256 is an interventional study that assigns participants to a tested intervention. The registered 533 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (31% lower).
The record links to 0 conditions, and to 1 intervention - of which rimonabant is the first listed.
NCT00464256 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00464256 about?
NCT00464256 is a clinical study titled "Comparison of Efficacy and Safety of Rimonabant 20mg/Day Versus Placebo in Smoking Cessation". The primary objective is to assess the efficacy a 20mg/day fixed dose of rimonabant versus placebo on abstinence from tobacco use in cigarette smoker. The secondary objective is to evaluate the effects of rimonabant on craving and weight and on the clinical and biological safety and tolerability of...
What is the current status of trial NCT00464256?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 533 participants. The study started on 2004-04. Estimated completion is 2004-11.
What interventions are being tested in trial NCT00464256?
The interventions under investigation include: rimonabant (DRUG).
Who is sponsoring clinical trial NCT00464256?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00464256's enrollment target sits among peer trials
533 704th of 2000 higher than 1,297 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04910685 · 534 participants · Phase 2
(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
- NCT06128551 · 534 participants · Phase 1
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- NCT05793151 · 532 participants · NA
Multi-Site Trial of Navigation vs Treatment as Usual to Improve Initiation of Timely Adjuvant Therapy
- NCT06378866 · 532 participants · Phase 2
Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia